Yamanouchi/Merck Awarded Attorneys' Fees In Pepcid Patent Challenge
Executive Summary
Schein Pharmaceutical's Pepcid patent challenge was ruled "without adequate foundation and speculative at best" by federal court Judge Richard Owen in his Oct. 1 decision to award attorneys' fees to patent holders Yamanouchi and Merck.
You may also be interested in...
Generic Firms Warned Of First-To-File Risk: Willful Infringement Cases Rising
The pressure on generic companies to be first-to-file in patent challenges will lead to a "boom" in willful infringement cases against generics makers, an industry attorney maintains
Generic Firms Warned Of First-To-File Risk: Willful Infringement Cases Rising
The pressure on generic companies to be first-to-file in patent challenges will lead to a "boom" in willful infringement cases against generics makers, an industry attorney maintains
Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees
Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions